News
- October 26, 2012
- License Agreement of SGLT2 Inhibitor "CSG452" in Japan
- June 06, 2012
- A consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd., started marketing Livalo (pitavastatin), a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Taiwan on June 1, 2012.
A regulatory approval was obtained in January 2011. - May 09, 2012
- A consolidated subsidiary of Mitsubishi Tanabe Pharma，P.T. Tanabe Indonesia，started marketing Livalo (pitavastatin)，a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Indonesia on May 1, 2012.
The launch comes after P.T. Tanabe Indonesia received regulatory approval in November 2011. - February 20, 2012
- Eli Lilly has introduced Redevant (pitavastatin), an HMG-CoA reductase inhibitor for lowering cholesterol, in Mexico this month.
The launch comes after the product received approval in July 2011 from the country's Ministry of Health.
